Aducanumab approval and withdrawal (2021-2024)
The FDA approved aducanumab on June 7, 2021, the first drug cleared for removing amyloid plaques from the brain. The agency's own advisory committee had voted against it, and two large trials had been stopped for futility before a post hoc analysis found benefit at a high dose. Medicare then limited coverage to patients enrolled in clinical trials.
Few patients received the drug, and Biogen halved the price.
Biogen discontinued aducanumab and shifted its Alzheimer's effort to lecanemab.
It set the evidentiary bar the class still works against: clearing plaques is not enough unless a clinical benefit survives scrutiny.
